Cardiovascular: Stroke Circulatory System
Conditions
Interventions
This is a placebo-controlled, double-blind, randomised pilot study based within two rehabilitation stroke units. Eligible patients will be randomised to receive either dexamphetamine or placebo, with
Sponsors
Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients aged 18 years and over newly admitted to the stroke units in Bradford and Leeds will be assessed by a research assistant for potential recruitment. Eligible subjects will 1. have had a new stroke resulting in a right or left-sided weakness of sufficient severity to require an anticipated minimum 4-week stay on the stroke unit. 2, have a Computed Tomography (CT) scan to exclude intracranial haemorrhage 3. be medically stable and able to participate in daily rehabilitation.
Exclusion criteria
Exclusion criteria: 1. unable to understand language as a result of stroke 2. any memory impairment (pre-existing or as a consequence of the stroke) 3. stable heart disease and untreated high blood pressure 4. any psychiatric treatment within the past 5 years or a past history of drug or alcohol dependence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The extent to which a subject's weakness has recovered at 3 months after the stroke. Interim assessments will occur at 3 and 6 weeks after beginning the trial medication. Assessment of recovery will document residual weakness of the affected arm, trunk and leg (using the Rivermead motor assessment scale) and the subject's degree of independence in basic activities of daily living (using the Barthel Index). In parallel, the subjects mood state will be assessed for depression and lack of motivation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed